Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 27,968 shares at $146.25 ($4.1M) on 2015-11-20, disclosed to the SEC on 2015-11-24.
Scheduled sale ($4.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $144.12 | 12,325 | $1.8M | 43.5% |
| 2 | $145.28 | 2,700 | $392K | 9.6% |
| 3 | $146.25 | 1,700 | $249K | 6.1% |
| 4 | $147.15 | 1,000 | $147K | 3.6% |
| 5 | $145.13 | 500 | $73K | 1.8% |
| 6 | $146.00 | 550 |
| $80K |
| 2.0% |
| 7 | $147.50 | 2,000 | $295K | 7.2% |
| 8 | $148.10 | 5,628 | $834K | 20.4% |
| 9 | $149.21 | 1,465 | $219K | 5.4% |
| 10 | $150.00 | 100 | $15K | 0.4% |
| Total | $145.86 avg | 27,968 | $4.1M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |